Sugi Predict

Sugi Predict / Compounds / SCHEMBL14916592

SCHEMBL14916592

SCHEMBL14916592

Cn1cnc2c(Br)cc(Cl)cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.42
▸ POLB P06746 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ GRM2 Q14416 1/20 0.39
▸ C1S P09871 1/20 0.37
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ GFER P55789 1/20 0.36
▸ CDK1 P06493 1/20 0.35
▸ F2RL3 Q96RI0 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ DPP4 P27487 1/20 0.33
▸ YTHDC1 Q96MU7 1/20 0.33
▸ GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27249977 0.81 POLB (0.41) RECQLPOLBL3MBTL1NPC1RAB9A
SCHEMBL3758387 0.79 C1S (0.38) RECQLPOLBL3MBTL1C1SNPC1
SCHEMBL31541896 0.78 C1S (0.39) RECQLPOLBL3MBTL1C1SCDK1
SCHEMBL31009407 0.78 C1S (0.39) RECQLPOLBL3MBTL1C1SALDH1A1
SCHEMBL24750131 0.78 C1S (0.39) RECQLPOLBL3MBTL1C1SALDH1A1
SCHEMBL29938479 0.76 GRM2 (0.43) RECQLL3MBTL1GRM2C1SF2RL3
SCHEMBL24750133 0.76 GRM2 (0.43) RECQLL3MBTL1GRM2C1SF2RL3
SCHEMBL34471659 0.75 RECQL (0.40) RECQLPOLBL3MBTL1C1SCDK1
SCHEMBL22125661 0.74 MEN1 (0.37) RECQLPOLBL3MBTL1NPC1RAB9A
SCHEMBL25217401 0.74 MEN1 (0.40) RECQLC1SMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025016391-A1 THIAZOLE PYRAZINE COMPOUNDS AND USE THEREOF 南京再明医药有限公司 2025-01-23 — — WO disclosed
EP-2773640-B1 BICYCLIC PIPERAZINE COMPOUNDS HOFFMANN LA ROCHE (CH) 2015-08-19 — — EP disclosed
EP-2773640-B1 BICYCLIC PIPERAZINE COMPOUNDS HOFFMANN LA ROCHE (CH) 2015-08-19 — — EP disclosed
EP-2773640-A1 BICYCLIC PIPERAZINE COMPOUNDS Hoffmann-La Roche AG (CH) 2014-09-10 — — EP disclosed
US-8722676-B2 Bicyclic piperazine compounds GENENTECH, INC. (US) 2014-05-13 — — US disclosed
US-8722676-B2 Bicyclic piperazine compounds GENENTECH, INC. (US) 2014-05-13 — — US disclosed
WO-2013067260-A1 BICYCLIC PIPERAZINE COMPOUNDS GENENTECH, INC. (US) 2013-05-10 — — WO disclosed
US-20130116262-A1 BICYCLIC PIPERAZINE COMPOUNDS GENENTECH, INC. (US) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116262-A1 BICYCLIC PIPERAZINE COMPOUNDS BTK, LCK, SYK RECQL 2723/4885POLB 1248/4885L3MBTL1 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.